Rationale: Soluble guanylyl cyclase (sGC) generates cyclic guanosine monophophate (cGMP) upon activation by nitric oxide (NO). Cardiac NO-sGC-cGMP signaling blunts cardiac stress responses, including pressureoverload-induced hypertrophy. The latter itself depresses signaling through this pathway by reducing NO generation and enhancing cGMP hydrolysis.
H eart failure affects more than 6 million patients in the United States alone, and its prevalence continues to rise despite recent diagnostic and therapeutic advances. A leading risk factor for the disease is chronic pressure overload due to arterial hypertension, which afflicts nearly a third of the world's population. Such sustained stress often induces pathological hypertrophy of the chamber wall and can lead to depressed function and electric instability. Current treatment reduces the pressure load and suppresses neurohormones that contribute to maladaptive remodeling. However, clinical outcome remains poor, and as a consequence, novel ap-proaches to leverage intrinsic negative modulators of hypertrophy are garnering increasing attention.
One such pathway involves the second messenger cyclic guanosine monophosphate (cGMP). [1] [2] [3] Cyclic GMP is generated by either the particulate guanylyl cyclase (pGC) linked to the natriuretic peptide receptor, or "soluble" GC (sGC), activated by nitric oxide (NO). Once generated, cGMP can modulate cardiomyocyte function by interacting with phosphodiesterases (PDEs) that regulate cAMP and its associated pathways, or by activating its primary target kinase, protein kinase G (PKG, also called cGK-1). Cyclic GMP-PKG activation plays a key role in modulating vascular tone and confers antifibrotic effects. Newer studies support a potent role in suppressing cardiomyocyte pathobiology, including blunting in vivo pressure-overload-induced hypertrophy and protecting against ischemia-reperfusion injury and myocyte apoptosis. 4 -11 However, in chronic pressure overload, myocardial NO synthesis and secondary signaling through cGMP is itself depressed 9, [12] [13] [14] [15] [16] probably contributing to the pathophysiology. The latter appears related in part to an increase in cGMP hydrolysis by targeting phosphodiesterases such as PDE1 and PDE5. 9, 15, 16 Another key component of this signaling pathway is sGC itself, yet no prior studies have examined its activity or potential modulators of activity in cardiac hypertrophy. Although sGC-derived cGMP is mostly thought to accumulate in the cytosol, some NO-stimulated cGMP production is detectable at the plasma membrane. [17] [18] [19] In endothelial cells, endothelial NO synthase (NOS3) and PKG colocalize with caveolin, an integral membrane scaffolding protein that compartmentalizes and concentrates signaling molecules within specialized regions of the plasma membrane. This has suggested that caveolae, small (50 -100 nm) flask-like lipidand protein-rich invaginations of the plasma membrane, may serve as microdomains for optimized NO-sGC-cGMP signaling. 20 In this regard, sGC has been found at the plasma membrane in rat neurons, rat vascular endothelial cells, human and rat skeletal myocytes, rat cardiac myocytes, and human platelets. 19 -23 The importance of this localization and whether it is impacted by heart disease to contribute to altered sGC function is unknown.
The present study tested the hypothesis that sustained pressure overload depresses NO-stimulated sGC activation and explored mechanisms for such change including loss of NO-and heme-dependent activity and shifts in microdomain localization. We reveal novel evidence for both, revealing a shift of sGC out of caveolae-enriched membrane microdomains after sustained pressure overload, with enhanced sGC oxidation, and net depression of NO-stimulated cGMP generation.
Methods
Full details can be found in the Methods section of the Online Data Supplement at http://circres.ahajournals.org.
Animal Model
Male C57BL/6 mice (age, 9 -12 weeks, Jackson Labs, Bar Harbor, ME) were used. Pressure overload was produced by transverse aortic constriction (TAC) as previously described. 9 Left ventricular (LV) cardiac tissue of caveolin-3 null 24 (Cav3 KO background strain C57BL/6 mice) and littermate controls (wild-type [WT]) mice were provided by JF Jasmin (Thomas Jefferson University). 25 All animals received humane care according to National Institutes of Health guidelines, and all animal protocols were approved by the respective IACUCs of Johns Hopkins University and Temple University.
Physiological Study
Cardiac function was assessed in conscious and isoflurane-anesthetized mice by transthoracic, 2D, M-mode echocardiography (Acuson Sequoia C256, Siemens at Johns Hopkins and Vevo660, Visual Sonics at Temple) with a 15-MHz linear-array transducer. M-mode LV end-systolic and end-diastolic dimensions were averaged from 3 to 5 beats. LV percent fractional shortening (FS) and mass were calculated as described previously. 9
Immunofluorescent and Confocal Microscopy
Immunohistochemical analysis was performed on paraffinembedded, 10% formaldehyde gravity-perfused LV tissue. LV tissue slices were imaged with a Nikon C-1 PLUS confocal microscope system.
Cell Fractionation
Protein was prepared from snap-frozen heart tissue, and membranecytosol fractionation was performed as previously described. 9, 26 
Isolation of Caveolin-Enriched Lipid Raft Fraction
Caveolin-enriched lipid raft fractions (Cav3 ϩ LR) were prepared from freshly harvested and snap-frozen LV tissue, using a discontinuous 35-5% sucrose density gradient ultracentrifugation method as previously described, 27 with some modifications.
Western Blot Analysis
Protein extracts from LV tissue homogenate and above mentioned subfractions were run on SDS-PAGE gels and transferred to nitrocellulose membranes. Immunoblot analysis was performed using primary antibody probes as detailed in the Online Data Supplement.
sGC Activity and cGMP Measurement
Baseline and agonist-stimulated cGMP levels of total LV, Cav3 ϩ LR, and nonenriched fractions (NLR) from Sham, TAC, WT, and Cav3 KO hearts were measured by direct cGMP ELISA kit from New East Biosciences (Malvern, PA).
Statistical Analysis
All values are expressed as meanϮSEM. Statistical analyses were performed using Student t test, 1-way ANOVA followed by Tukey test when comparing multiple groups, or 2-way ANOVA when determining interaction of conditions. For data sets with unequal variances, a Welch t test was used. Statistical significance was defined as PϽ0.05. 
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Results
Cardiac sGC Activity Declines in Hypertrophied Myocardium Despite Preserved Overall Myocardial sGC␣ 1 and ␤ 1 Expression
C57BL/6J mice subjected to 3 weeks of transverse aortic constriction (TAC) 9 developed LV hypertrophy, systolic dysfunction, and dilatation ( Figure 1A ), as previously reported. 9, 28 The capacity to stimulate myocardial sGC was assessed by the change in cGMP generation before and after exposure to NO, using the NO-donor diethylamine NONOate (DEA/NO, 1 mol/L) in the presence of the broad PDE inhibitor IBMX (3-isobutyl-1-methylxanthine, 0.75mmol/L). Mean baseline cGMP was Ϸ40% lower after TAC (Table 1) , but this disparity was markedly amplified on DEA/NO stimulation ( Figure 1B) , with a 10-fold higher NO-stimulated response in sham versus TAC. As a control, tissue extracts were pretreated with the selective, irreversible, heme-site sGC inhibitor 1H-[1,2,4] oxadiazolo[4,3a]quinoxalin1-one (ODQ at 10, 30, and 90 mol/L), which blocked NO-stimulated cGMP by 80 -90% (Online Figure I ).
Because TAC induces myocardial oxidative stress 13 and oxidation of the sGC heme moiety suppresses its NO-stimulated activity, 29 we tested whether this may have contributed to the response in TAC hearts. sGC was activated in an NO-and heme-independent manner by BAY 60 -2770 (0.1mol/L) 30 in the presence of IBMX ( Figure 1B ). BAY 60 -2770 induced similar cGMP production as with DEA/NO in sham controls but also triggered this response in TAC heart lysate. This indicates that the depressed DEA/NO response in TAC probably is not related to reduced sGC expression per se but rather to sGC heme-oxidation.
To confirm whether sGC expression was in fact unaltered by TAC, immunoblots were performed using specific column-purified antibodies to the ␣ 1 -subunit 31 or ␤ 1subunit. Functional sGC exists as a heterodimer with an ␣ (73-82 kDa) and ␤ subunit (70 kDa), the latter reportedly expressed diffusely within cells and necessary for NO responsiveness. 32, 33 The ␣ 1 ␤ 1 isoform is the most ubiquitously expressed across tissue types and the only isoform in myocardium. 34 Negative controls were provided using heart tissue from mice genetically lacking either sGC␣ 1 35 or sGC␤ 1 31 ( Figure 1C ). We found expression of sGC ␣ 1and ␤ 1 -subunits, relative to GAPDH, was unaltered by TAC ( Figure 1D ).
Myocardial sGC Localizes in Cytosolic and Membrane Compartments
Given unchanged protein expression, we next questioned whether TAC alters the subcellular distribution of either or both sGC subunits. LV extracts from sham and TAC mice were subfractionated into cytosol and membrane compartments and analyzed by immunoblot ( Figure 2A ). 36 GAPDH and Cav3 served as markers for cytosol and membrane fractions, respectively. In both sham and TAC hearts, the total cytosol-to-membrane ratio of sGC␣ 1 expression was similar, with approximately 66% in cytosol, 33% in the membrane ( Figure 2B ). This is consistent with prior studies performed in rat myocardium 19 and frog cardiomyocytes. 18 In contrast, sGC␤ 1 distribution was slightly altered by TAC. In sham hearts, sGC␤ 1 was nearly equally divided between cytosol and membrane fractions (47Ϯ3.4% in cytosol, 53Ϯ3.4% in membrane). In TAC hearts, sGC␤ 1 distribution was predominantly cytosolic, with about 60% of total sGC␤ 1 localized in the cytosol and 40% in the membrane fraction (Pϭ0.018 versus sham). 1 and ␤ 1 subunits. A, LV mass, fractional shortening, and LV end-diastolic diameter of sham (nϭ31) and TAC (nϭ48) mice at baseline and 3 weeks after surgery as measured by echocardiography. LV mass to body weight ratio: *PϽ0.0002 versus baseline; †PϽ0.002 versus respective sham; ‡PϽ0.00001 versus sham. B, sGC activity of total protein from sham and TAC hearts in response to NO-donor DEA/NO 1 mol/L (nϭ15 for sham, 14 for TAC) and NO-and heme-independent sGC activator BAY 60 -2770 0.1 mmol/L (nϭ7 for sham, 6 for TAC). *PϽ0.01 versus respective DEA/NO; †PϽ0.00001 versus respective sham. C and D, Western immunoblots and normalized densitometry analysis of total sGC␣ 1 and sGC␤ 1 expression in sham (nϭ9 for ␣ 1 , nϭ6 for ␤ 1 ) and TAC (nϭ10 for ␣ 1 , nϭ6 for ␤ 1 ). Data are meanϮSEM. 
Tsai et al Stress-Induced Oxidation/Relocalization of sGC
Confocal immunohistochemistry of formaldehyde perfusion-fixed LV tissue revealed colocalization of sGC␣ 1 with Cav-3 in sham hearts at both plasmalemma and T-tubular membranes ( Figure 2C ). In TAC hearts, sGC␣ 1 remained present at both membrane sites though colocalization with Cav3 appeared slightly disrupted. By contrast, sGC␤ 1 was distributed diffusely throughout the myocardium in a longitudinal pattern, displaying some colocalization with Cav3. This did not appear altered by TAC.
Pressure Overload Stress Alters Membrane Microdomain Localization of sGC␤ 1 Subunit
To more directly examine whether sGC localization within plasma membrane compartments is altered by TAC, we determined the distribution of sGC␣ 1 and sGC␤ 1 in microdomains of sham and TAC hearts (Figure 3 ). Sham and TAC LV homogenates were subjected to detergent-free, discontinuous 35-5% sucrose density gradient centrifugation to separate caveolae-enriched lipid raft microdomains (F4 and F5, Cav3 ϩ LR) from nonenriched domains (F11, NLR). Each sucrose density gradient fraction was run in equal volume on SDS-PAGE electrophoresis ( Figure 3B ). Protein concentrations determined by Bradford assay confirmed that total protein distribution was weighted toward heavier fractions (F6 and higher) lacking Cav3 in both control and TAC hearts ( Figure 3C ). In sham controls, sGC␣ 1 and sGC␤ 1 were detected in caveolae-enriched and nonenriched microdomains. In sham controls, the distribution of sGC␣ 1 , sGC␤ 1 , and Cav3 across fractions revealed sGC␣ 1 and sGC␤ 1 to be relatively higher in Cav3 ϩ LR after normalizing to total protein within the respective fraction. However, in TAC hearts, the proportion of sGC␤ 1 present in Cav3 ϩ LR declined ( Figure 3D and 3E ).
Pressure-Overload Cardiac Stress Differentially Reduces NO-Induced sGC Activity in Caveolae-Enriched Lipid Raft and Nonenriched Microdomains
To test whether membrane microdomain localization of sGC influenced its functional response to NO, Cav3 ϩ LR and NLR fractions were assayed for NO and BAY 60 -2770 -stimulated cGMP generation ( Figure 4 ). As before, measurements were made in the presence of IBMX, so cGMP generation could be stably detected. Baseline cGMP in respective caveolae-enriched or nonenriched microdomains were similar between sham and TAC (Table 1) . However, cGMP levels were Ϸ3-fold higher in caveolae-enriched microdomains (Pϭ0.01 for sham, Pϭ0.04 for TAC). More strikingly, NO-stimulated cGMP production was markedly greater in caveolae-enriched versus nonenriched fractions, and this was observed in sham and TAC similarly (note logarithmic scale). However, NO-induced sGC activity was also uniformly higher in sham Cav3 ϩ LR and NLR fractions compared to corresponding domains in TAC hearts (PϽ0.05 on paired Student t test for all NLR measurements versus respective Cav3 ϩ LR). In contrast to NO stimulation, the sGC response to BAY 60 -2770 was Ͼ10-fold greater in NLR than Cav3 ϩ LR fractions, and this held similarly for sham and TAC hearts. In NLR fractions, the BAY 60 -2770 response exceeded that to DEA/NO, whereas in Cav3 ϩ LR fractions, the 2 responses were similar. This pattern persisted after TAC. BAY 60 -2770 activates sGC in a heme-independent manner, and this response is enhanced by heme-oxidation, 30, 37 supporting greater sGC oxidation in NLR fractions, be they in sham or TAC hearts. With TAC, the concordant reduction in both NO and BAY 60 -2770 responsiveness of Cav3 ϩ LR fraction is consistent with a shift of sGC away from caveolaeenriched into nonenriched microdomains. Two-way ANOVA of the cGMP responses to DEA/NO in the caveolae-enriched and nonenriched microdomains of sham and TAC hearts revealed that both pressure-overload and microdomain localization affected sGC NO-responsiveness (PϽ0.001 for both), with a borderline interaction effect (Pϭ0.06). This disparity is further quantified in Table 2 . An increase in the BAY 60 -2770 -to-DEA/NO relative responses occurs with hemeoxidation. Within Cav3 ϩ LR fractions, this relative response ratio was unaltered by TAC; however, it dramatically rose in NLR fractions.
Loss of Caveolin 3 Blunts sGC NO Responsiveness Specifically in Lipid Raft Fractions
To further test whether caveolae represent enhanced microdomains for NO-inducible sGC activity, we studied sGC responsiveness in hearts of caveolin-3 null (Cav3KO) mice. The model develops spontaneous mild cardiac hypertrophy by 4 months of age. 38 For whole myocardial analysis, we examined 6-month-old hearts, which had a Ͻ10% higher LV/body weight ratio, well below that induced by TAC ( Figure 1A) . Myocardial DEA/NO-induced sGC activity was nearly 90% lower in Cav3KO versus WT ( Figure 5A) , whereas the BAY 60 -2770 response was identical between groups ( Figure 5A ). This appeared similar to what we observed with TAC, and supports greater sGC oxidation in the absence of a Cav3-microdomain pool. There was a trend toward reduced protein expression of sGC␣ 1 in Cav3KO (Pϭ0.052), whereas sGC␤1 was unchanged over controls ( Figure 5B ). However, as the BAY 60 -2770 response was similar between groups, total sGC heterodimer probably was unaltered. We next examined sGC activity in membrane microdomains, using the same fractions F4/F5 versus F11 to define the 2 compartments. The DEA/NO response was much less in Cav3KO over WT in the F4/F5 fraction ( Figure 5B ), whereas both responses were lower but equal in the F11 (NLR) fraction. Interestingly, the response to BAY 60 -2770 was also reduced in Cav3KO F4/F5 fractions, whereas in the F11 NLR fraction, it was higher (as in controls and TAC) and similar to littermate controls. The marked decline in the BAY 60 -2770 response in F4/F5 fractions in Cav3KO was not due to an absence of sGC in this microdomain, as Western blots of sucrose density gradient fractions ( Figure 5D ) revealed the presence of each subunit in both microdomains (F4/F5 and F11). This suggests that Cav3 provides an important facilitating function to NO/heme-dependent and independent sGC activation. 
Discussion
This study investigated whether and how the activation of myocardial soluble guanylyl cyclase is affected by pressureoverload-induced cardiac hypertrophy. The results highlight several novel and important findings. First, sGC is profoundly modified in the hypertrophied heart, rendering it less NO-responsive yet equally activated by the NO-and hemeindependent agonist BAY 60 -2770 as compared with controls. This supports the presence of oxidation of sGC, which, though previously documented in the pulmonary and systemic hypertension, 29, 30 has not been previously reported in the myocardium. Second, we reveal the presence of a substantial proportion of myocardial sGC in the plasma membrane within microdomains that confer differential activation properties in the normal heart. Specifically, sGC within Cav3-enriched microdomains is more responsive to NO activation and relatively protected from oxidation. By contrast, sGC in nonlipid raft (non-Cav3 containing) domains is less NO responsive and more oxidized. Caveolae-localization of sGC as a mechanism to augment NO responsiveness is consistent with prior work showing colocalization of sGC with NOS3 and PKG 19, 20 and NO-cGMP signaling within plasmalemmal caveolae. Third, we link the 2 behaviors, showing that this submembrane distribution of sGC is dynamic, being diminished in Cav3 ϩ LR domains by pressure overload, resulting in a shift from NO to BAY 60 -2770 sGC-responsiveness. Thus, although heme-oxidation contributes to the overall decline of NO activation of sGC in the hypertrophied heart, this modulation occurs predominantly in noncaveolae enriched microdomains. Last, we show that the presence of Cav3 within lipid rafts is an important regulator of both NO/heme-dependent and heme-independent sGC activation. Viewed together, these observations shed new light on how abnormal subcellular distribution and oxidation of sGC can contribute to depressed cGMP-related signaling in cardiac disease.
Despite its name and differentiation from particulate GC coupled to natriuretic receptors, soluble GC is also detectable in membrane fractions. The ␣ 2 ␤ 1 sGC isoform is found in placenta, epithelia, and neurons and has been shown in rat neuronal synaptic membrane. 21 The ␣ 1 ␤ 1 heterodimer is more ubiquitously expressed, 34 and is also detected in the plasmalemma of vascular endothelial cells, 19 platelets, 19 neuroblastoma cells, 39 and sarcolemma of skeletal, 22, 23 smooth, 40 and cardiac muscle tissue. 18, 19 The specific function of membrane-associated versus cytosolic sGC␣ 1 ␤ 1 has been relatively little studied. Zabel et al 19 first identified a translocation of sGC to caveolin-enriched domains in endothelial cells when NO synthesis was stimulated by calcium, and this in turn enhanced cGMP-generation. Castro et al also observed an NO-sGC-cGMP signal in cardiomyocyte subplasmalemma by expressing an olfactory cyclic nucleotide gated membrane channel, though this was considered the particulate (eg, NP-coupled) GC, 41 and not sGC. Other studies have revealed compartmentalized NO-stimulated sGC-cGMP pools that blunt ␤-adrenergic stimulation modulated by PDE5a, 42 PDE2, 43 and ␤3-adrenergic signaling, 43, 44 suggesting colocalization at the plasma membrane. Whether this functional compartment includes sGC has not been tested. In another study, bovine tracheal smooth muscle showed membraneassociated sGC␣ 1 ␤ 1 produces the first of 2 sequential cGMP signals involved in muscarinic activation, involving sGC translocation from cytosol to the plasma membrane. 40 How sGC moves remains unclear, though it is found in a complex with NOS3 and heat shock protein 90 (HSP90) 45 and HSP90 can act as a migration chaperone. Clarification of this mechanism awaits further investigation.
The present study is the first to identify differential NO/heme-dependent and heme-independent activation properties of sGC localized within or external to Cav3 ϩ LR microdomains. Strikingly, although sGC heme-oxidation appears prevalent in the NLR fraction with TAC, this appears not the case in Cav3 ϩ LR. The cause for an apparent protection against oxidation of sGC in the Cav3 ϩ LR versus greater oxidation in NLR domains remains unknown. Interestingly, superoxide dismutase 1 has been reported to localize to caveolae in vascular endothelial cells 46 and may confer targeted antioxidant effects. Another study found thioredoxin reductase 1 binds to caveolin-1, 47 though in this instance the interaction was suggested to impede rather than enhance antioxidant activity. As NOS is also localized to this microdomain and can be the target of oxidation depressing its function, 13 it seems plausible that a protected Cav3 ϩ LR microdomain would facilitate NO-sGC interaction and cGMP generation, as we observed. The Cav3KO results further suggest that Cav3 itself plays an important role to this preservation, whether heme/NO dependent or not. The latter may relate to a structural organization of the proteins within caveolae, which become disrupted by elimination of Cav3. Cav3KO mice develop mild cardiac hypertrophy, LV dilatation, and reduced systolic function, 38 whereas cardiacspecific overexpression of Cav3 attenuates pressure-overload hypertrophy, 48 both supporting a cardioprotective role of Cav3. Whether other members of the caveolae subproteome also change with chronic cardiac stress (or perhaps aging) remains unknown but raises an intriguing possibility in the context of abnormal signal transduction in various forms of cardiac hypertrophy and disease.
The exact stoichiometry of sGC subunits in the myocyte microdomains remains unknown, and this is nontrivial to quantify given the isolation procedures involved. Furthermore, we recognize that expression of each isoform does not determine their net balance in a heterodimer, and that this balance may itself alter activation. The shift of ␤ 1 more than ␣ 1 from the Cav3-microdomain suggests that some change in heterodimer composition may have occurred. In the rat brain, postnatal development has been associated with decreased sGC activity despite unaltered sGC subunit expression, and for the cerebrum, this has correlated with less sGC␣ 1 ␤ 1 heterodimerization. 49 In the human heart, sGC␣ 1 gene expression is nearly 3-fold higher than sGC␤ 1 (sGC␣ 2 is undetectable). 34 Our findings support this, suggesting sGC␤ 1 may determine sGC NO-responsiveness through heterodimerization with a relative surplus of the ␣ 1 subunit.
Pressure overload has been previously shown to depress NOS activity through functional uncoupling 13 and to augment phosphodiesterase-mediated cGMP hydrolysis. 9 Based on the current data, pressure-overload also results in sGC oxidation and disrupted localization away from Cav3 ϩ LR microdomains-further depressing NO-stimulated responsiveness. Each mechanism can play a role in reducing effective cGMP signaling and thus contribute to cardiac stress maladaptations. Because we cannot yet directly manipulate sGC membrane translocation, its in vivo effects on cardiac stress responses admittedly remain speculative. The new results do not conflict with prior observed benefits from PDE5 or PDE1 inhibition 9, 50 or from reversing NOS uncoupling by tetrahydrobiopterin (BH4). 51 In the former case, the effect was due to enhancing cGMP once generated, which in turn increased PKG activity. By contrast, BH4 reduced NOS-derived ROS and enhanced NO synthesis, but this did not lead to increased PKG activation. It is possible that persistent sGC dysfunction contributed to this observation. Further studies will be required to test whether reverse remodeling of the hypertrophied heart can restore normal sGC NO sensitivity and relocalize it to Cav3 ϩ LR. The present results should help frame such research by highlighting a new sGC regulatory mechanism and providing insights into the potential utility of heme-independent sGC activators for the treatment of heart disease. 
